
Dyad Medical develops and deploys cloud-based AI-powered software for automated cardiac image analysis and interpretation. Their platform, Libby®, integrates into existing clinical workflows, offering clinicians a more efficient and consistent method for diagnosing heart conditions across various imaging modalities including Echocardiogram (Echo:Prio™), Cardiac Magnetic Resonance Imaging (CMR), Intravascular Optical Coherence Tomography (IVOCT), and Computed Tomography (CT). The company aims to reduce misdiagnosis, minimize healthcare costs, and provide universal access to expert-level cardiac analysis. Dyad Medical has achieved FDA clearance for its Echo:Prio™ application and has also received FDA clearance for its IVOCT application. The company was founded by Ronny Shalev and is based in Boston, MA.

Dyad Medical develops and deploys cloud-based AI-powered software for automated cardiac image analysis and interpretation. Their platform, Libby®, integrates into existing clinical workflows, offering clinicians a more efficient and consistent method for diagnosing heart conditions across various imaging modalities including Echocardiogram (Echo:Prio™), Cardiac Magnetic Resonance Imaging (CMR), Intravascular Optical Coherence Tomography (IVOCT), and Computed Tomography (CT). The company aims to reduce misdiagnosis, minimize healthcare costs, and provide universal access to expert-level cardiac analysis. Dyad Medical has achieved FDA clearance for its Echo:Prio™ application and has also received FDA clearance for its IVOCT application. The company was founded by Ronny Shalev and is based in Boston, MA.
Sector: AI-powered cardiac medical imaging software
Flagship product: Libby® platform (Echo:Prio™ echocardiography app)
Founded / HQ: 2018 — Boston, Massachusetts
Regulatory: FDA 510(k) clearances for Echo:Prio™ and IVOCT application
Latest disclosed funding: $3.5M seed (Oct 2020)
CEO / Founder: Ronny Shalev, PhD
Clinical cardiac imaging interpretation and workflow efficiency
2018
Healthtech / Medical imaging software
$3,500,000
Participation from Social Starts L.P. and local angel investors; company-stated total funding (including NIH grants) exceeds $3.5M as of Oct 2020.
“Seed round led by The Unofficial Syndicate with participation from Social Starts L.P. and local angel investors”